New study shows weight-loss drugs rewire brain circuits to curb cravings for alcohol and sex.

New research indicates that weight-loss medications are fundamentally altering brain chemistry to suppress cravings not only for food but also for alcohol and sexual activity. While patients typically seek GLP-1 agonists such as Ozempic, Wegovy, and Mounjaro to regulate blood sugar and slow digestion, these drugs mimic the hormone glucagon-like peptide-1 to signal satiety and curb appetite.

A study conducted by researchers at the University of Virginia reveals that newer oral formulations of these agents can directly rewire neural circuits responsible for reward and motivation. This neurological restructuring may explain the efficacy of the drugs in controlling obesity while also accounting for side effects like nausea and a diminished interest in vices including gambling and sex. Dr. Ali D. Güler, the lead neuroscientist author, stated, "This is just the beginning." He added that understanding these pathways could lead to treatments targeting specific behaviors, ranging from overeating to addiction and impulse control.

Although the investigation utilized mouse models with GLP-1 receptors engineered to mimic human biology, the implications extend to human health. The team tested danuglipron from Pfizer and orforglipron, marketed as Foundayo by Eli Lilly. Notably, Pfizer halted development of danuglipron after an asymptomatic participant in a trial suffered potential drug-induced liver injury.

The significance of these findings is underscored by current usage statistics: approximately one in eight US adults, or roughly 31 million people, have used GLP-1 medications at least once. This demand exists against a backdrop where the Centers for Disease Control and Prevention estimates that three in four Americans are overweight or obese, with over 36 million living with type 2 diabetes. Dr. Güler emphasized that while the drugs are undeniably effective, the critical question remains what they are doing inside the human brain.

Experts remain uncertain whether the pharmaceutical company will authorize additional studies on the drug. Previous research indicates that newer GLP-1 medications target neurons within the hindbrain. This specific region plays a vital role in regulating feelings of fullness and nausea. The research team discovered that these drugs also activate a distinct neural circuit. This pathway connects the hindbrain directly to the central amygdala. The central amygdala is a structure responsible for processing complex emotions. It also contains neurons that produce dopamine, a neurotransmitter governing the body's reward system. Stimulating this specific pathway significantly reduces dopamine release in the brain. Lower dopamine levels help curb cravings and stop compulsive overeating behaviors. Güler emphasized that this circuit is essential for assigning value to rewarding experiences. These experiences often involve consuming high-calorie foods that provide immediate pleasure. Earlier studies suggest GLP-1 users may lose interest in other addictive behaviors. Such behaviors include substance use, gambling, and sexual activity. Consequently, this research may explain unexpected side effects observed in some patients. "What we show is that these drugs can reduce not just hunger, but the desire to pursue rewarding food," he stated. "They're acting on the system that makes you want the cake, not just the system that makes you feel full." Researchers also proposed that these findings could explain varying side effects among different GLP-1 drugs. Some users experience severe nausea while others feel little discomfort at all. Although most current GLP-1 treatments require injection, major companies are developing oral options. Pharmaceutical giants like Pfizer and Eli Lilly are racing to create cheaper alternatives. Güler believes these newer formulations could offer benefits extending far beyond simple weight loss. "If these drugs are affecting reward pathways in the brain, that has implications beyond weight loss," he noted. "It could influence things like addiction, impulse control or even how people experience pleasure." "These are powerful compounds. We need to understand them fully as they move into everyday use.